228 related articles for article (PubMed ID: 33539551)
1. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M
Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551
[TBL] [Abstract][Full Text] [Related]
2. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.
Herman SE; Niemann CU; Farooqui M; Jones J; Mustafa RZ; Lipsky A; Saba N; Martyr S; Soto S; Valdez J; Gyamfi JA; Maric I; Calvo KR; Pedersen LB; Geisler CH; Liu D; Marti GE; Aue G; Wiestner A
Leukemia; 2014 Nov; 28(11):2188-96. PubMed ID: 24699307
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
5. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
6. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Gallais F; Ysebaert L; Despas F; De Barros S; Dupré L; Quillet-Mary A; Protin C; Thomas F; Obéric L; Allal B; Chatelut E; White-Koning M
Clin Pharmacokinet; 2020 Sep; 59(9):1171-1183. PubMed ID: 32328976
[TBL] [Abstract][Full Text] [Related]
8. Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
Smith DD; Goldstein L; Cheng M; James DF; Kunkel LA; Fardis M; Hamdy A; Izumi R; Buggy JJ; Clow F
Ann Hematol; 2015 Feb; 94(2):249-56. PubMed ID: 25178517
[TBL] [Abstract][Full Text] [Related]
9. In Human Visualization of Ibrutinib-Induced CLL Compartment Shift.
Mayerhoefer ME; Haug A; Jäger U; Pichler V; Pfaff S; Wester HJ; Hacker M; Kazianka L; Staber PB
Cancer Immunol Res; 2020 Aug; 8(8):984-989. PubMed ID: 32580942
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
DiSogra KY; Tran T; Arnall JR; Janes A; Moore DC; Park SI
J Oncol Pharm Pract; 2021 Jul; 27(5):1265-1269. PubMed ID: 33106104
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
Wodarz D; Garg N; Komarova NL; Benjamini O; Keating MJ; Wierda WG; Kantarjian H; James D; O'Brien S; Burger JA
Blood; 2014 Jun; 123(26):4132-5. PubMed ID: 24829205
[TBL] [Abstract][Full Text] [Related]
14. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
Parikh SA; Achenbach SJ; Call TG; Rabe KG; Ding W; Leis JF; Kenderian SS; Chanan-Khan AA; Koehler AB; Schwager SM; Muchtar E; Fonder AL; McCullough KB; Nedved AN; Smith MD; Slager SL; Kay NE; Finnes HD; Shanafelt TD
Cancer Med; 2020 May; 9(10):3390-3399. PubMed ID: 32187452
[TBL] [Abstract][Full Text] [Related]
15. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
16. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
17. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
Mateu-Albero T; Juárez-Sánchez R; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C; Cuesta-Mateos C
Cancer Immunol Immunother; 2022 Mar; 71(3):627-636. PubMed ID: 34297159
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
19. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Chen TL; Harrington B; Truxall J; Wasmuth R; Prouty A; Sloan S; Lehman AM; Sampath D; Orlemans E; Baiocchi RA; Alinari L; Byrd JC; Woyach JA; Hertlein E
J Hematol Oncol; 2021 Feb; 14(1):36. PubMed ID: 33627156
[TBL] [Abstract][Full Text] [Related]
20. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
